Edition:
United States

TG Therapeutics Inc (TGTX.OQ)

TGTX.OQ on NASDAQ Stock Exchange Capital Market

11.40USD
24 Mar 2017
Change (% chg)

$0.50 (+4.59%)
Prev Close
$10.90
Open
$10.95
Day's High
$11.52
Day's Low
$10.95
Volume
419,828
Avg. Vol
287,434
52-wk High
$15.05
52-wk Low
$4.10

Latest Key Developments (Source: Significant Developments)

TG Therapeutics Inc Q4 loss per share $0.48
Friday, 10 Mar 2017 07:30am EST 

TG Therapeutics Inc : TG Therapeutics Inc announces fourth quarter and year-end 2016 financial results and business update . Qtrly loss per share $0.48 . TG Therapeutics Inc - cash, cash equivalents, investment securities, and interest receivable were $45.0 million as of December 31, 2016 . Q4 earnings per share view $-0.36 -- Thomson Reuters I/B/E/S .TG Therapeutics Inc - cash, cash equivalents, as of Dec 31, 2016 will be sufficient to fund planned operations for approximately next 24 months.  Full Article

TG Therapeutics prices $50 mln offering of common stock
Thursday, 9 Mar 2017 09:19am EST 

Tg Therapeutics Inc : TG Therapeutics announces pricing of $50 million public offering of common stock .Pricing of an underwritten public offering of 5.13 million shares of its common stock at a price of $9.75 per share.  Full Article

TG Therapeutics announces proposed public offering of common stock
Wednesday, 8 Mar 2017 04:01pm EST 

TG Therapeutics Inc :TG Therapeutics announces proposed public offering of common stock.  Full Article

TG Therapeutics' leukemia drug clears hurdle in late-stage study
Monday, 6 Mar 2017 07:00am EST 

TG Therapeutics Inc : TG Therapeutics announces positive topline data from phase 3 genuine study of TG-1101 in combination with ibrutinib in patients with high risk chronic lymphocytic leukemia (CLL) . TG Therapeutics - study met its primary endpoint, with tg-1101 (ublituximab) plus ibrutinib increasing overall response rate (ORR) by >70% over ibrutinib alone . TG Therapeutics - combination was well tolerated with a safety profile consistent with phase 2 study of ublituximab plus ibrutinib . TG Therapeutics Inc- full analysis of phase 3 genuine data along with detailed efficacy and safety results will be submitted for presentation at a medical meeting in first half of 2017 .TG Therapeutics - and company plans to meet with FDA as soon as possible thereafter to discuss filing of data for accelerated approval.  Full Article

TG therapeutics announces completion of enrollment and B-cell depletion data from part 1 of ongoing phase 2 multiple sclerosis study
Wednesday, 11 Jan 2017 07:30am EST 

TG Therapeutics Inc : TG therapeutics announces completion of enrollment and B-cell depletion data from part 1 of ongoing phase 2 multiple sclerosis study . TG Therapeutics Inc says phase 3 MS program planned to initiate in 1H 2017 . TG Therapeutics Inc says TG-1101 was well tolerated with no grade 3/4 adverse events reported . TG Therapeutics Inc says early data demonstrates rapid and profound B-cell reductions in ms patients treated with TG-1101 with median B-cell reduction of 99% .As part 2 of trial, company has added expansion cohorts and will explore accelerated dosing of initial 150mg dose.  Full Article

TG Therapeutics announces positive DSMB recommendation
Tuesday, 22 Nov 2016 07:30am EST 

TG Therapeutics Inc : TG Therapeutics announces positive DSMB recommendation for continuation of the UNITY-CLL phase 3 trial . Still targeting completion of enrollment in first half of 2018 .TG Therapeutics announces positive DSMB recommendation for continuation of the UNITY-CLL phase 3 trial.  Full Article

TG Therapeutics amends phase 3 clinical trial
Thursday, 13 Oct 2016 07:00am EDT 

TG Therapeutics Inc : TG Therapeutics Inc. Amends genuine phase 3 clinical trial to accelerate study completion by revising primary endpoint to overall response rate . TG Therapeutics Inc- enrollment expected to be completed before year end 2016 with top-line data available in first half of 2017 . TG Therapeutics - if results of revised genuine study are positive, plans to file a bla for accelerated approval based on outcome of pre-BLA meeting . FDA agrees that overall response rate (orr) data from revised genuine study can be used to request pre-BLA meeting . TG Therapeutics - amendments expected to save co more than $10 million over next 2 years, and allow company to focus its resources on unity-CLL program . TG Therapeutics Inc- company believes it could file a BLA in first half of 2018 .TG Therapeutics Inc - target enrollment for genuine phase 3 trial has been reduced to approximately 120 randomized patients.  Full Article

TG Therapeutics Q2 GAAP loss per share $0.33
Monday, 8 Aug 2016 07:30am EDT 

TG Therapeutics Inc : TG Therapeutics Inc announces second quarter 2016 financial results and business update . Q2 GAAP loss per share $0.33 .Q2 earnings per share view $-0.29 -- Thomson Reuters I/B/E/S.  Full Article

TG Therapeutics says first patient enrolled in UNITY-DLBCL phase 2b trial
Tuesday, 7 Jun 2016 07:30am EDT 

TG Therapeutics Inc :Announces first patient enrolled in registration-directed UNITY-DLBCL phase 2b trial.  Full Article

TG Therapeutics enters into collaboration to develop and commercialize Novel BET inhibitors
Friday, 27 May 2016 07:30am EDT 

TG Therapeutics Inc : Enters into a global collaboration to develop and commercialize Novel BET inhibitors developed by Jubilant Biosys for the treatment of hematological malignancies . Under terms of agreement, TG Therapeutics will pay an up-front licensing fee of $1 million . Additional payments contingent on certain milestones of up to approximately $177 million .TG Therapeutics will also provide funding to support certain targeted research efforts at Jubilant Biosys.  Full Article

More From Around the Web

BRIEF-TG Therapeutics Inc Q4 loss per share $0.48

* TG Therapeutics Inc announces fourth quarter and year-end 2016 financial results and business update